This is a detailed report on the recent U.S. Preventive Services Task Force (USPSTF) recommendation statement on the use of aspirin, one of two stories we reviewed on this topic (here’s the other, from CBSNEWS.com). It is a relatively thorough discussion, with an impressive array of physicians parsing the guidelines and informing us who is likely, or not likely to benefit from taking aspirin, the likelihood of benefit and harm, and the importance of gauging one’s personal set of risk factors before deciding if a daily aspirin is right for you.
One issue this story could have made clearer is the quality of evidence behind the task force’s recommendations. Some important limitations are discussed, but not in a direct way. This issue–the relatively thin evidence behind the recommendations–made the rounds among physician news sites, and ideally would have been emphasized more in general news coverage.
Aspirin is widely prescribed or purchased over-the-counter for aches and pains, and increasingly used to prevent cardiovascular events, such as heart attack and stroke, over the long term. Better public understanding of the benefits and harms of aspirin, and clearer delineations of the science around who is likely to benefit from taking it, are all likely to have an important health impact.
It is universally known that aspirin is cheap, sold widely and in a manner where its cost will not be a barrier to consumption, so the cost information is not necessary to reiterate in this report.
One of the commentators, Charles Hennekens, gave an excellent summary of the quantified benefits citing both absolute and relative numbers.
As above, Hennekens gave a description of the absolute harms involved in aspirin, particularly related to gastrointestinal bleeding, and several of the other sources also discussed this important harm.
While it could have been discussed in a more direct way, some important limitations to the quality of the evidence in the task force’s recommendation can be inferred by various statements from the sources in this story. For example, Hennekens states that “the totality of the evidence is incomplete,” and that the evidence in the task force report hasn’t advanced much since the 1980s. He also cites ongoing studies that will hopefully fill in some of these gaps. Other sources in the story discuss how complex the evidence is.
There is no evidence of disease mongering here, as cardiovascular disease is the top cause of death in the U.S. for both women and men.
We applaud the breadth of sourcing in this piece. Readers are told that Kirsten Bibbins-Domingo, is the vice-chair of the US Preventive Services Task Force, and she weighs in with her assessment. Other physicians, however, seem independent of the USPSTF and are unlikely to be financially conflicted with the manufacturers of aspirin.
Alternatives are mentioned (smoking cessation, eating a balanced diet, getting sufficient exercise), and that’s sufficient to rate as Satisfactory. The piece would be strengthened by comparing the relative benefits of the other options.
It’s pretty clear that aspirin is ubiquitous and sold almost everywhere as an over-the-counter drug, so we’ll rate this one N/A. This story, and the other we reviewed, might have benefited from mentioning that the drug has a generic name (known as ASA or acetylsalicylic acid). Generic versions of the drug do exist, are likely cheaper than the brand name, and equally effective.
There are no spurious claims made here about the “novelty” of aspirin’s effects, or the recommendations in the report, yet maybe a bit of confusion when one of the physicians said that aspirin’s effects on colorectal cancer were “provocative.” What is a reader to make of that relatively unhelpful statement? This could have been clearer.
With a full slate of outside observers commenting on this study, it is unlikely to be overly reliant on any news release.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like